Weidong Yin, Chairman, CEO and President of Sinovac, commented, We have become proud to be providing our H1N1 vaccine to the Chinese federal government and are confident that people can complete the national H1N1 vaccine stockpiling job regularly. We continue to work at our objective of providing residents of China with affordable, international-quality vaccines. The contract with the Shanghai Municipal Center for Disease Control and Prevention brings us nearer to our goal since it exposed another important public marketplace in China. .. China places third buy order for H1N1 vaccine with Sinovac Biotech Sinovac Biotech Ltd. , a respected provider of biopharmaceutical items in China, today that it provides received its third purchase order for its H1N1 vaccine announced, PANFLU.1, from China’s Ministry of Industry and IT for the nationwide stockpiling plan.‘This finding provides great guarantee for better focusing on how keloids function and provide a potential focus on for improved and novel treatments,’ says study lead author Lamont R. Jones, M.D., Vice Chair, Division of Neck and Otolaryngology-Head Surgery in Henry Ford. ‘We now have a better understanding of how this gene fits in the broader picture of the wound healing process, which may be essential in preventing scars in general.’ Study outcomes will be shown today, Jan. 23, at the 2015 Triological Combined Sections Meeting in San Diego. Related StoriesPerisylvian polymicrogyria gene foundResearchers determine inherited gene variation connected with pediatric severe lymphoblastic leukemiaApoE4-carrying men with Alzheimer's disease vulnerable to brain bleedsKeloid scars type raised, firm epidermis areas and most often take place on the chest, shoulders, earlobes , upper arms and cheeks.